Pattern Bioscience

Pattern interviewed Cindy Lopez, director of people and culture, about building a workplace during challenging times and beyond. The interview begins with her professional background.

The designation advances the company’s Urine (UTI) ID/AST Panel on Pattern’s single-cell microbiology platform.

Working at Pattern is a rare opportunity to build something meaningful and lasting for all of humanity.

Nick Arab - Chief Executive Officer

The company advances single-cell microbiology to make targeted antimicrobial treatment information available days sooner.

The company says its team will respond to contact inquiries shortly and directs job inquiries to its Careers page.

Pattern Bioscience will deliver the fastest ever phenotypic ID/AST

Pattern Bioscience, Inc.’s privacy policy explains how it collects, uses, and shares information from users of its websites. Website use is also subject to its Terms of Use.

Pattern Bioscience secures FDA Breakthrough Device Designation for its Urine ID/AST Panel, marking the company’s second assay to earn this recognition. The designation accelerates regulatory review for innovative medical devices that provide significant improvements over existing technologies.

Sep 2026Pattern BioscienceNews article

Pattern Bioscience appoints **David Barreca** as Vice President of Sales to expand its US commercial team. The company prepares for FDA submission of its **single-cell microbiology platform** and plans to launch the **Pneumonia ID/AST Panel**, targeting faster bacterial infection diagnostics. Barreca brings leadership experience in diagnostics to support Pattern’s growth phase.

Jul 2026Pattern BioscienceNews article

Pattern Bioscience enrolls over 1,000 samples in a pivotal U.S. clinical trial for its rapid pneumonia diagnostic panel, targeting critically ill patients. The culture-free, phenotypic identification and antimicrobial susceptibility testing (ID/AST) tool aims to support a 510(k) submission. This milestone marks the halfway point in the trial’s enrollment phase.

Mar 2026Pattern BioscienceNews article

Pattern Bioscience secures **$43 million in Series D funding** from investors including AMR Action Fund, Illumina Ventures, and Omnimed Capital. The capital advances development of its **FDA-cleared rapid pneumonia diagnostic**, enabling identification and antibiotic susceptibility testing. The company plans to use the funds for **U.S. clinical trials and a 510(k) submission** to accelerate regulatory approval.

Nov 2025Pattern BioscienceNews article